Clinical trial
Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis
NCT00141830 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00141830 |
|---|---|
| Title | Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis |
| Official title | A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | Methotrexate plus ERB-041 for 12 weeks, Placebo for 12 weeks |
| Enrollment | 159 |
| Start date | Aug 1, 2005 |
| Primary completion | Oct 19, 2006 |
| Completion | Oct 19, 2006 |
| First posted | Sep 1, 2005 |
| Last update posted | Sep 29, 2020 |
| Countries | Canada, Hungary, Italy, Mexico, Spain, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: